Table 2.
Baseline characteristics of the study sessions
| BNT162b2 mRNA COVID-19 vaccine (1st dose) | BNT162b2 mRNA COVID-19 vaccine (2nd dose) | Sham vaccine | p-value Vaccine (1st dose) vs. placebo and Vaccine (2nd dose) vs. placebo | |
|---|---|---|---|---|
| Brachial systolic pressure (mmHg) | 115.4 ± 11.6 | 120.3 ± 13.9 | 115.00 ± 16.2 | 0.88 and 0.02 |
| Brachial diastolic pressure (mmHg) | 71.8 ± 8.8 | 74.4 ± 9.3 | 69.7 ± 8.7 | 0.26 and 0.01 |
| Mean pressure (mmHg) | 86.7 ± 8.1 | 89.7 ± 10.0 | 84.6 ± 9.9 | 0.22 and 0.003 |
| Heart Rate (beats/min) | 73.8 ± 10.1 | 75.4 ± 11.4 | 71.4 ± 9.4 | 0.11 and 0.01 |
| Central systolic pressure (mmHg) | 102.1 ± 9.0 | 105.5 ± 11.1 | 101.0 ± 12.9 | 0.61 and 0.01 |
| Central diastolic pressure (mmHg) | 72.9 ± 8.7 | 75.9 ± 9.4 | 70.9 ± 8.8 | 0.27 and 0.007 |
| Augmentation index corrected for heart rate at 75 bpm (%) | 10.5 ± 12.7 | 9.9 ± 11.5 | 8.0 ± 12.2 | 0.11 and 0.25 |
| Carotid-femoral pulse wave velocity (m/s) | 7.0 ± 1.6 | 6.5 ± 1.0 | 6.8 ± 1.4 | 0.18 and 0.16 |
| Brachial artery flow-mediated dilatation (%) | 9.7 ± 3.9 | 9.8 ± 3.8 | 10.0 ± 3.4 | 0.76 and 0.81 |
| Brachial artery hyperemic mean blood flow velocity (cm/s) | 43.9 ± 21.7 | 50.0 ± 12.1 | 53.0 ± 20.1 | 0.08 and 0.48 |
| High-sensitivity C-reactive protein (mg/L) | 1.00 (0.55–2.30) | 0.80 (0.45–1.80) | 0.90 (0.45–1.80) | 0.12 and 0.76 |
Variables as mean value ± SD for normally distributed and median value (25th–75th percentile) for skewed variables. Vaccine (1st dose) vs. placebo and vaccine (2nd dose) vs. placebo baseline sessions were compared using the paired Student’s t test for normally distributed variables and with Wilcoxon Signed Rank test for skewed variables.